Granulomatosis with Polyangiitis News and Research

RSS
Researchers reveal promising biomarker for vascular disease relapse

Researchers reveal promising biomarker for vascular disease relapse

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA-approved drug improves clinical outcomes among patients with rare immunologic disease

FDA-approved drug improves clinical outcomes among patients with rare immunologic disease

Two new studies on eosinophilic granulomatosis with polyangiitis selected by Vasculitis Foundation

Two new studies on eosinophilic granulomatosis with polyangiitis selected by Vasculitis Foundation

New study launched to find impact of vasculitis on employment, income

New study launched to find impact of vasculitis on employment, income

NICE approves MabThera for treating severe forms of GPA and MPA

NICE approves MabThera for treating severe forms of GPA and MPA

Vasculitis damage swift, accumulating

Vasculitis damage swift, accumulating

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Powerful new option for treating vasculitis

Powerful new option for treating vasculitis

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

ANCA-associated vasculitis not a single clinical entity

ANCA-associated vasculitis not a single clinical entity

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

Psychological stress can trigger flares of vasculitis

Psychological stress can trigger flares of vasculitis

Roche Canada grants Vasculitis and Scleroderma Fellowship

Roche Canada grants Vasculitis and Scleroderma Fellowship

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Rituxan receives FDA approval for treating two rare diseases

Rituxan receives FDA approval for treating two rare diseases

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

NIAID doctor receives Will Rogers Institute's award for outstanding contributions to lung research

NIAID doctor receives Will Rogers Institute's award for outstanding contributions to lung research

Rituxan drug effective for treating ANCA-associated vasculitis

Rituxan drug effective for treating ANCA-associated vasculitis

Men get autoimmune diseases, too!

Men get autoimmune diseases, too!